Lifecore to hold special meeting April 10 to remove Series A preferred conversion cap

LIFECORE BIOMEDICAL, INC. DE

Special meeting on April 10, 2025 to vote on removing the 19.99% conversion cap on Series A Convertible Preferred Stock.
If approved, up to 6,056,284 common shares could be issued upon conversion at the current conversion price.
No holders have elected to convert as of Jan 17, 2025; company has no plans to raise additional equity capital.
Board sets record date of Feb 18, 2025 for voting eligibility.
Proposal needed to comply with Nasdaq Listing Rule 5635(d) regarding issuance over 19.99% of outstanding common.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.